Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γδ T Cells for Relapse Prevention in High-Risk AML Post-Transplant
NCT07237230Recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of allogeneic gamma-delta T cells in acute myeloid leukemia (AML). Primary endpoint: Relapse-Free Survival at 2 years. Started Jul 2025; status: recruiting.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07237230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07237230.